124 CHAPTER 7 REFERENCES 1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. 2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383(9921):955– 62. 3. Grymonprez M, Simoens C, Steurbaut S, De Backer TL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: A systematic review and meta-analysis. Europace. Oxford University Press; 2022;24:887–98. 4. Joosten LPT, de Boer AR, van Eerde EJB, van Doorn S, Hoes AW, Bots ML, et al. Atrial fibrillation: Trends in prevalence and antithrombotic prescriptions in the community. Netherlands Heart Journal. 2022;30:459–65. 5. Savelieva I, Fumagalli S, Kenny RA, Anker S, Benetos A, Boriani G, et al. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2023;25(4):1249–76. 6. Proietti M, Romiti GF, Raparelli V, Diemberger I, Boriani G, Vecchia LAD, et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. Ageing Research Reviews. 2022:79:101652. 7. Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of atrial fibrillation for older people with frailty: A systematic review and meta-analysis. Age and Ageing. 2019;48:196– 204. 8. He L, He R, Huang J, Zou C, Fan Y. Impact of frailty on all-cause mortality and major bleeding in patients with atrial fibrillation: A meta-analysis. Ageing Research Reviews. 2022:73:101527. 9. Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: A cohort study. Ann Intern Med. 2021;174(9):1214–23. 10. van den Dries CJ, van Doorn S, Souverein P, Pajouheshnia R, Moons KGM, Hoes AW, et al. The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation. TH Open. 2020;4:e417–26. 11. Bul M, Shaikh F, McDonagh J, Ferguson C. Frailty and oral anticoagulant prescription in adults with atrial fibrillation: A systematic review. Aging Medicine. 2023;6:195–206. 12. Joosten LPT, Van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL, et al. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: Rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open. 2019;9(12):e032488. 13. Steverink N, Slaets J, Schuurmans H, van Lis M. Measuring frailty: Developing and testing the GFI (Groningen Frailty Indicator). Gerontologist. 2001;41(1):236–7. 14. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis. 2005;3(4):692–4.
RkJQdWJsaXNoZXIy MTk4NDMw